Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
Commentary|Videos|October 2, 2024
Retrospective Radiotherapy in IBD Data May Warrant Prospective Research
Author(s)Bhupesh Parashar, MD
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Advertisement
Advertisement
CancerNetwork® spoke with Bhupesh Parashar, MD, a physician professor, vice-chair of research, and co-director of the head and neck cancer service in Radiation Medicine at the Center for Advanced Medicine of Northwell Health Cancer Institute, about the next steps in researching modern radiotherapy techniques in patients with inflammatory bowel disease (IBD) treated for pelvic malignancies.
Related to this article
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
Advertisement
Advertisement